General Information of the Compound
| Compound ID |
CP0519264
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
DORDAVIPRONE
Show/Hide
|
||||||||||||||||||
| Synonyms |
1342897-86-2
1616632-77-9
2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
3388AH
7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one
9U35A31JAI
AK174891
AKOS025404904
AOB2892
AS-16735
CS-3564
EX-A669
FT-0700231
GTPL9978
HY-15615A
J-690224
KB-335104
MolPort-039-137-731
NSC 350625
ONC 201
ONC201
ONC201(TIC10 isomer)
Onc-201
SCHEMBL16227974
TIC 10
TIC 10 active isomer
TIC10
TIC10(ONC-201)
UNII-9U35A31JAI
ZINC169620396
s7963
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C24H26N4O
|
||||||||||||||||||
| Molecular Weight |
386.499
|
||||||||||||||||||
| Canonical SMILES |
Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
VLULRUCCHYVXOH-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
1616632-77-9
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Clinical Information about the Compound
Drug 1 ( ONC201 )
| Drug Name | ONC201 | ||
|---|---|---|---|
| Company | Oncoceutics Philadelphia, PA | ||
| Indication | |||
| Target(s) | |||